FDA Grants Approval for Paliperidone ANDA205402 by I3 PHARMS
The FDA has granted approval for ANDA205402, a generic formulation of paliperidone, submitted by I3 PHARMS.
Asset
FDA
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's approval of a generic formulation of paliperidone by I3 PHARMS introduces a new competitor in the antipsychotic market. This could significantly affect pricing strategies and market share for existing branded products, necessitating a strategic response from portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timing and pricing strategies of I3 PHARMS, as well as responses from competitors.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.